This new round will enable the French biotech company to license-out its isolation technologies for complex therapeutic targets and viral antigens
Starting from native material or recombinant systems, we succeed with all types of membrane proteins: GPCRs, Ion Channels, Transporters, Receptors and Viral Proteins.